Search results | chugai


Partnering Agreements with Chugai

This report provides all the information you require to better understand Chugai and its partnering interests and activities over the past seven years.


Chugai Pharmaceutical: Partnering activity 2009-2014

Chugai Pharmaceutical, headquartered in Japan, is a subsidiary of Roche, having operations in Asia, Europe and North America. This company is now ranked as a Top 50 Pharma company by Current Partnering.

Chugai Pharmaceutical Ltd – Japan’s number one biopharmaceutical company

Chugai Pharmaceutical manufactures, sells, imports and exports pharmaceuticals and has become the leading biopharmaceutical company in Japan.

Roche drops business merger rumors with Chugai Pharmaceutical

Roche had business merger rumors to buy Tokyo-based Chugai Pharmaceutical Co., Ltd. appear to be tabled for now. Sources in Roche indicated the company was focused on its $8.3 billion acquisition of California-based InterMune Inc.

Roche to buy 40% stake in Chugai Pharma

Roche Holding is in talks to buy the almost 40 percent of Chugai Pharmaceutical that it doesn’t already own to gain full control of its Japanese partner for oncology and arthritis drugs, according to people familiar with the matter.

Chugai: Company Profile

Chugai,a top biopharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

A review of the Top 50 Pharma companies of 2014

The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango

PDL Biopharma: Capitalizing on the humanization of monoclonal antibodies

PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology.   

Roche committed to innovation and growth

Roche will give an update on its strategy, which continues to be focused on medical innovation and sustainable growth. Through its leadership in personalised healthcare, Roche is uniquely positioned to develop therapies that advance current standards of care and improve people’s lives.


Sorry, your search returned no results.


Athersys and Chugai in Multistem cell therapy pact

Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan

Athersys and Chugai announce pharma licensing deal for ischemic stroke

Athersys and Chugai Pharmaceutical have announced a partnership and pharma licensing agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.

Romark and Chugai Pharmaceutical enter exclusive licensing deal for nitazoxanide in Japan

Chugai has paid an upfront payment to Romark, and will make additional payments based on the achievement of certain clinical and regulatory milestones. Romark will participate in profits from product sales in Japan through a supply agreement and royalties.

Chiome Bioscience and Chugai in research agreement

Chiome and Chugai will develop novel value-added therapeutic monoclonal antibodies employing Chiome’s ADLib® (Autonomously Diversifying Library) System and will apply the System to assessment of target proteins and lead generation of products for clinical use.

Licensing agreement for ISPRI and Optimatrix platform for de-risking biologics

Chugai Pharmaceutical signed an agreement with EpiVax to incorporate EpiVax’s ISPRI immunogenicity screening and deimmunization technology into Chugai’s drug development toolbox.